Kohei Takano

Kohei Takano

Auto-generated profile, based on publicly available information

Kohei Takano

Daiichi Sankyo Co., Ltd., Tokyo, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KTKohei Takano
Kohei Takano
YMYoichi Munehira
Yoichi Munehira
MHMana Hatanaka
Mana Hatanaka
RMRyo Murakami
Ryo Murakami
YSYoshihiro Shibata
Yoshihiro Shibata
YKYasuyuki Kaneta
Yasuyuki Kaneta
Patients with melanoma with activating BRAF mutations (BRAF V600E/K) initially respond to combination therapy of BRAF and MEK inhibitors. However, their clinical efficacy is limited by acquired resistance, in some cases driven by amplification of the mutant BRAF gene and subsequent reactivation of the MAPK pathway. DS03090629 is a novel and orally available MEK inhibitor that inhibits MEK in an ATP-competitive manner. In both in vitro and in vivo settings, potent inhibition of MEK by DS03090629 or its combination with the BRAF inhibitor dabrafenib was demonstrated in a mutant BRAF-overexpressing melanoma cell line model that exhibited a higher MEK phosphorylation level than the parental cell line and then became resistant to dabrafenib and the MEK inhibitor trametinib. DS03090629 also exhibited superior efficacy against a melanoma cell line–expressing mutant MEK1 protein compared with dabrafenib and trametinib. Biophysical analysis revealed that DS03090629 retained its affinity for the MEK protein regardless of its phosphorylation status, whereas the affinity of trametinib declined when the MEK protein was phosphorylated. These results suggest that DS03090629 may be a novel therapeutic option for patients who acquire resistance to the current BRAF- and MEK-targeting therapies.

9 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
KTKohei Takano
Kohei Takano
MYMayuko Yukiura
Mayuko Yukiura
KTKazuki Takahashi
Kazuki Takahashi
MKMichiko Kitamura
Michiko Kitamura
HOHiroko Okuno
Hiroko Okuno
TAToshinori Agatsuma
Toshinori Agatsuma
Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).


3 April 2023
Verified
Other
Open access
KTKohei Takano
Kohei Takano
YMYoichi Munehira
Yoichi Munehira
MHMana Hatanaka
Mana Hatanaka
RMRyo Murakami
Ryo Murakami
YSYoshihiro Shibata
Yoshihiro Shibata
YKYasuyuki Kaneta
Yasuyuki Kaneta
Supplementary Figures from Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma

2 January 2026
Verified
Other
Open access
KTKohei Takano
Kohei Takano
MYMayuko Yukiura
Mayuko Yukiura
KTKazuki Takahashi
Kazuki Takahashi
MKMichiko Kitamura
Michiko Kitamura
HOHiroko Okuno
Hiroko Okuno
TAToshinori Agatsuma
Toshinori Agatsuma
Amino acid sequences of anti-TA-MUC1 antibody.

2 January 2026
Verified
Other
Open access
KTKohei Takano
Kohei Takano
MYMayuko Yukiura
Mayuko Yukiura
KTKazuki Takahashi
Kazuki Takahashi
MKMichiko Kitamura
Michiko Kitamura
HOHiroko Okuno
Hiroko Okuno
TAToshinori Agatsuma
Toshinori Agatsuma
Correlation analysis of the efficacy of DS-3939a and TA-MUC1 expression in evaluated PDX models.